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Salivary Gland Mucosa-Associated Lymphoid Tissue–Type 
Lymphoma From Sjögren’s Syndrome Patients in the Majority 
Express Rheumatoid Factors Affinity-Selected for IgG
Richard J. Bende,1  Jerry Janssen,1  Anna Beentjes,1  Thera A. M. Wormhoudt,1 Koen Wagner,2   
Erlin A. Haacke,3 Frans G. M. Kroese,3 Jeroen E. J. Guikema,1  and Carel J. M. van Noesel1
Objective. Patients with Sjӧgren’s syndrome (SS) have an increased risk of developing malignant B cell 
lymphomas, particularly mucosa- associated lymphoid tissue (MALT)–type lymphomas. We have previously shown 
that a predominant proportion of patients with SS- associated salivary gland MALT lymphoma express somatically 
hypermutated IgM with strong amino acid sequence homology with stereotypic rheumatoid factors (RFs). The present 
study was undertaken in a larger cohort of patients with SS- associated MALT lymphoma to more firmly assess the 
frequency of RF reactivity and the significance of somatic IGV-region mutations for RF reactivity.
Methods. B cell antigen receptors (BCRs) of 16 patients with SS- associated salivary gland MALT lymphoma were 
analyzed. Soluble recombinant IgM was produced of 12 MALT lymphoma samples, including 1 MALT lymphoma 
sample that expressed an IgM antibody fitting in a novel IGHV3-30–encoded stereotypic IGHV subset. For 4 of 
the 12 IgM antibodies from MALT lymphoma samples, the somatically mutated IGHV and IGKV gene sequences 
were reverted to germline configurations. Their RF activity and binding affinity were determined by enzyme- linked 
immunosorbent assay and surface plasmon resonance, respectively.
Results. Nine (75%) of the 12 IgM antibodies identified in patients with SS- associated salivary gland MALT 
lymphoma displayed strong monoreactive RF activity. Reversion of the IGHV and IGKV mutations to germline 
configuration resulted in RF affinities for IgG that were significantly lower for 3 of the 4 somatically mutated IgM 
antibodies. In stereotypic IGHV3-7/IGKV3-15–encoded RFs, a recurrent replacement mutation in the IGKV3-15–third 
complementarity- determining region was found to play a pivotal role in the affinity for IgG- Fc.
Conclusion. A majority of patients with SS-associated salivary gland MALT lymphoma express somatically 
mutated BCRs that are selected for monoreactive, high-affinity binding of IgG-Fc. These data underscore the notion 
that soluble IgG, most likely in immune complexes in inflamed tissues, is the principal autoantigen in the pathogenesis 
of a variety of B cell lymphomas, particularly SS-associated MALT lymphomas.
INTRODUCTION
Mucosa- associated lymphoid tissue (MALT)–type lymphomas 
account for 5–10% of all B cell lymphomas. These lymphomas 
occur at various anatomic sites affected by chronic inflammation 
emerging from pathogens or autoimmunity (1–4). Among all auto-
immune diseases, Sjögren’s syndrome (SS) is most strongly associ-
ated with lymphoma development, in particular salivary gland MALT 
lymphomas (1–7). Clinical predictors of lymphoma development 
are swelling of the salivary glands, splenomegaly, lymphadenopathy, 
and palpable purpura. The main biologic predictors are cryoglob-
ulinemia, lymphopenia, low complement levels, and a monoclonal 
component in the serum or urine (3,4). Recently, the presence of 
rheumatoid factors (RFs) in the serum was identified as an inde-
pendent predictor of lymphoma development (8).
Previously, we have shown that ~40% of patients with sal-
ivary gland MALT lymphoma express near- identical (also called 
 stereotypic) B cell antigen receptors (BCRs), with a striking degree 
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of VH–third complementarity- determining region (CDR3) amino 
acid (aa) sequence homology with stereotypic RFs (9). Five groups 
of stereotypic RFs, each characterized by a canonical combina-
tion of IGHV and IGKV gene sequences and a distinct VH- CDR3, 
have been identified. They are encoded by 2 distinct IGHV1-69/
JH4 rearrangements, designated as V1- 69- RF and WOL- RF 
(also known as RFs of the Wa idiotype), and by IGHV3-7/JH3, 
IGHV4-59/JH2, and IGHV4-59/JH5 rearrangements, designated 
V3- 7- RF, V4- 59- RF, and V4- 59/JH5- RF, respectively (9,10). 
Stereotypic RF BCRs are also frequently expressed in gastric 
MALT lymphoma and hepatitis C virus (HCV)–related B cell lym-
phoma, and less frequently in ocular adnexal MALT lymphoma, 
splenic marginal zone B cell lymphoma, diffuse large B cell lym-
phoma, and B cell chronic lymphocytic leukemia (CLL) (9–15). 
Polyclonal stereotypic RFs are frequently present in HCV- infected 
patients with type II mixed cryoglobulinemia and in donors immu-
nized with mismatched red blood cells (16,17).
In a previous study by our group (9) and by Martin et  al 
(18), soluble IgM antibodies were recombinantly produced from 
SS-associated salivary gland MALT lymphomas of a total of 8 
patients, 6 of which showed strong monoreactive RF activity. 
Two of these 6 RFs were encoded by stereotypic RF IGHV rear-
rangements, i.e., V1- 69- RF and V3- 7- RF, respectively. Interest-
ingly, all of the RFs expressed either an IGKV3-15–encoded or 
IGKV3-20–encoded light chain, both of which are also typically 
expressed by IGHV3-7–encoded and IGHV1-69–encoded ste-
reotypic RFs.
In the present study, we assessed the configuration and 
specificity of the BCRs of 16 patients with SS-associated sali-
vary gland MALT lymphoma, and examined the contribution of 
the somatic mutations present in IGHV and IGKV on the affinity of 
RFs for IgG-Fc.
PATIENTS AND METHODS
MALT lymphoma tissue samples. Frozen salivary gland 
tissue samples from patients with SS- associated MALT lymphoma 
(patient samples M83, M86–M89, M91, and M93–M96) were 
obtained from the Departments of Pathology, Rheumatology, and 
Clinical Immunology at University Medical Center Groningen, The 
Netherlands. In addition, paraffin- embedded salivary gland tissue 
from 1 patient (sample M83) was obtained from the Department of 
Pathology at Haaglanden Medical Center, The Hague, The Neth-
erlands. The salivary gland samples from patients M5, M8, M11, 
M14, M21, and M22 have been described previously (9). Avail-
able serologic data from patients M86–M89, M91, and M93–M96 
showed that all were positive for IgM- RF, anti- SSA, and, except 
for patients M87 and M91, anti- SSB antibodies. Patients M91, 
M93, and M94 had low serum C4 levels (the patients’ immuno-
histochemical and serologic data are provided in Supplementary 
Table 1, available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41263/ abstract). 
Presence of IgM- RF and low levels of C4 are biologic predictors of 
lymphoma development (3,4,8).
The study was conducted in accordance with the ethics 
standards of our institutional medical ethics committee on human 
experimentation, as well as in accordance with the 1975 Declara-
tion of Helsinki, as revised in 1983.
Immunoglobulin gene analysis. Of the salivary gland tis-
sue from patients with SS- associated MALT lymphoma, Ig clonal-
ity was assessed by polymerase chain reaction (PCR). In addition, 
immunohistochemical analyses were used to detect light- chain 
restriction in those MALT lymphoma salivary gland samples show-
ing plasmacytic differentiation, with monotypic IgMκ expression 
observed in 10 samples (M5, M8, M11, M21, M83, M86, M91, 
M93, M94, and M95), and IgAκ expression in 2 samples (M14 
and M22). Salivary gland tissue from patient M96 expressed IgM, 
but immunohistochemical staining for the κ and λ light chains was 
indeterminate. In the samples from patients M87, M88, and M89, 
immunohistochemical staining for both the Ig heavy chain and Ig 
light chain was indeterminate (see Supplementary Table 1 [http:// 
onlinelibrary.wiley.com/doi/10.1002/art.41263/abstract]). How-
ever, in analyses by reverse transcription–PCR (RT- PCR) aimed at 
IgM, IgG, and IgA transcripts, it was found that the salivary gland 
tissue from patients M87, M88, and M89 expressed monoclonal 
IgM (Table 1).
In the paraffin- embedded salivary gland tissue obtained from 
patient M83, DNA was isolated using a QIAamp DNA Mini kit (Qia-
gen). RNA from all other MALT lymphoma salivary gland samples 
was isolated using TRI Reagent (Sigma- Aldrich, Merck), and com-
plementary DNA was synthesized using Pd(N)6 random primers 
and Moloney murine virus RT (Invitrogen, Fisher Scientific), accord-
ing to the manufacturer’s protocol. The rearranged IGHV genes 
were amplified using IGHV primers specific for the framework 
region 1 (FR1) and FR2, in combination with fluorochrome- labeled 
reverse primers specific for Ig JH and the constant regions of IgM 
(Cμ), IgG (Cγ), and IgA (Cα) (19). The IGHV PCR products were 
analyzed by gene scanning (VH- CDR3 spectratyping). In salivary 
gland samples M86–M89, M91, and M93–M96, the FR1/FR2 
PCR products with the Cμ primer yielded clonal IGHV PCR prod-
ucts. In the salivary gland tissue from patient M93, 2 clonal peaks 
were detected. The FR1/FR2 PCR with the Cγ primer yielded pol-
yclonal IGHV PCR products in all MALT lymphoma samples. The 
FR1/FR2 PCR Cα primer yielded polyclonal or oligoclonal IGHV 
PCR products in most of the MALT lymphoma samples. An FR1/
FR2 PCR with the Ig JH downstream primer was performed on the 
DNA sample from patient M83, which resulted in an IGHV PCR 
product with a monoclonal component. The clonal IGHV PCR 
products were sequenced using a Big Dye Terminator sequencing 
kit (ThermoFisher Scientific). The IGHV sequences were analyzed 
using V- Quest on the IMGT web site (http://www.imgt.org/) (20). 
IGKV PCR was performed with IGKV family–specific leader prim-
ers, combined with either Ig JK or Ig JK–constant region primers. 
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The IGKV sequences were analyzed using V- Quest on the IMGT 
web site.
Production of recombinant MALT lymphoma–
derived IgM antibodies. The IGHV sequences obtained using 
the FR1 × Cμ PCR products and appropriate IGHV family–specific 
leader primers, combined with an Ig JH primer, were used to pro-
duce full- length IGHV gene products. The full- length IGHV PCR 
products were obtained as described above. The complete IGHV 
and IGKV genes were cloned in pTOPO- TA plasmids and sub-
sequently in the pIGH(μ) and pIGL(κ) expression plasmids, which 
were then cotransfected in SP2/0 myeloma cells, as previously 
described (9). Supernatants of the transfected SP2/0 cells were 
screened for IgMκ production, using enzyme- linked immuno-
sorbent assays (ELISAs). The various IGHV and IGKV full- length 
sequences in which somatic mutations were reverted to germline 
configuration (as seen in salivary gland samples M91, M93, M94, 
and M96) were ordered from GenScript.
Antigen-­specific­ ELISA­ and­ antigen­ affinity­ mea-
surement. ELISA plates were coated overnight with human IgG 
(Sanquin), insulin from bovine pancreas, actin from bovine muscle, 
lipopolysaccharide (LPS) from Escherichia coli O55:B5 (Sigma- 
Aldrich, Merck), and SSA/Ro52 or SSA/Ro60 (Diarect) in coat-
ing buffer (0.05M Na2CO3, 0.05M NaHCO3, pH 9.6). The ELISA 
plates were incubated with recombinant lymphoma–derived IgM 
in serial dilutions starting from 1 μg/ml, and then subsequently 
incubated with horseradish peroxidase–conjugated mouse anti- 
human IgM (Southern Biotechnology), followed by development 
with tetramethylbenzidine as described previously (9,21).
Surface plasmon resonance assays were performed on an 
IBIS Mx96 instrument (IBIS Technologies) using a G- type anti–
human IgM chip. Data on the binding affinity of the IgM antibodies 
were processed as described previously (22).
RESULTS
IGHV and IGLV genes in salivary gland tissue from 
patients with SS- associated MALT lymphoma. We stud-
ied a panel of 16 salivary gland samples from patients with SS- 
associated MALT lymphoma; 6 of the IGHV and IGKV sequences 
had been determined previously (9). Of 10 remaining new MALT 
lymphoma salivary gland samples, IGHV and IGKV transcripts 
were amplified by RT- PCR using IGHV– and IGKV–specific prim-
ers in combination with primers specific for the constant region 
of the μ heavy chain and κ light chain, respectively. All 10 MALT 
lymphoma samples expressed IgM antibodies, and their respec-
tive IGHV sequences were assessed (Table 1). In 1 of the sam-
ples (M93), we identified 2 distinct clonal IGHV sequences. In 8 of 
the 10 samples, we were able to identify the corresponding IGKV 
















M83 IgM V3-74/D4-23/JH4; VK1-39/JK1 22; 9 C AREYGNSRFFDY WGQG;  
C QQSYTSPRT FGQG
12; 9 No
M86 IgM V3-30/D6-13/JH4; VK3-15/JK1 21; 11 C AQGAFSNKWYSIGDY WGQG; 
C QQYNNWPPWT FGQG
15; 10 Yes
M87 IgM V1-2/D5-18/JH5 17 C ARGQGTQVSHSWFDP WGQG 15 No
M88 IgM V1-69/D5-12/JH4 21 C AREGKASVANGAFDY WGQG 15 No
M89 IgM V4-59/D6-6/JH3; VK3-15/JK1 5; 5/7 C ARDIANIATRRDDAFDI WGQG; 
C QHYNNWPPWT FGQG
17; 10 Yes
M91 IgM V1-69/D5-24/JH4; VK3-20/JK2 7; 0 C ARKGGDRGDAYDVFDY WGQG; 
C QQYGSSPYT FGQG
16; 9 Yes
M93- I IgM V3-7/D3-22/JH3; VK3-15/JK1 6/9; 5 C ARGDYYDSGGS(S/N)YHDAFDV 
WGQG; C QHYNNWPPWT 
FGQG
19; 10 Yes
M93- II IgM V4-59/D3-10/JH5; VK4-1/JK2 12; 11 C ACGGGGSGTYFRGWFDP 
WGQG; C QQYYSTLYT FGQG
17; 9 No
M94 IgM V3-7/D3-22/JH3; VK3-15/JK1 10; 5 C ARGDYYDSSGYYIDAFDI 
WGQG; C QHYNNWPPWT 
FGQG
18; 10 Yes
M95 IgM V3-48/D3-22/JH3; VK3-15/JK4 18; 12 C AREPYSDSSSFFPGSFDI WGQG; 
C QQYDNWPLT FGGG
18; 9 No
M96 IgM V3-30.3/D2-8/JH3; VK3D-15/JK1 23/24; 4 C ARAGQGSNGIW(G/D)
GAFD(T/S) WGQG;  
C QHYNNWPPWT FGQG
17; 10 Yes
* Determined by reverse transcription–polymerase chain reaction. 
† Values are the number of mutations. Two values separated by a slash sign signify identification of molecular IGHV/IGKV clones harboring slightly 
different numbers of somatic mutations. 
‡ For the VH– and VK–third complementarity- determining region (CDR3) sequences in which 2 amino acids separated by a slash sign are depicted, 
this indicates that 2 molecular IGHV clones with dissimilar amino acids at this position were identified. 
§ Values are the number of amino acids. 
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sequences as well. Remarkably, 6 MALT lymphoma salivary gland 
samples expressed an IGKV3-15 rearrangement, and 1 expressed 
an IGKV3-20 rearrangement. IGKV3-15 and IGKV3-20 are typi-
cally found in IGHV3-7– and IGHV1-69–encoded stereo typic RFs, 
respectively (9). In the salivary gland samples from patients M87 
and M88, the IGKV PCR yielded polyclonal amplicons, most likely 
attributable to a relatively low tumor load, and thus we were pro-
hibited from reliably identifying the expressed IGKV sequences. All 
of the IGHV and IGKV genes identified were somatically mutated, 
except for the IGKV gene in the salivary gland tissue from patient 
M91, which was unmutated (Table 1 and Supplementary Figure 1, 
available on the Arthritis & Rheumatology web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41263/ abstract).
Findings of VH- CDR3 amino acid sequence homology 
studies. The VH- CDR3 aa sequences in the salivary glands from 
patients with MALT lymphoma were compared with the VH- CDR3 
aa sequences from GenBank (release 228), obtained using the 
NCBI Protein- BLAST algorithm. According to our arbitrary criteria, 
the VH- CDR3s were considered homologous when they shared 
at least 60% aa sequence homology, with an allowed maximal 
gap of 3 aa. Except for samples M83, M91, M93- II, and M96, the 
VH- CDR3 aa sequences in all other samples showed VH- CDR3 
homology with MALT lymphomas, but also with other B cell lym-
phomas such as CLL (see Supplementary Table 2, available on 
the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41263/ abstract). The VH- CDR3s in salivary 
gland samples M88, M93- I, M94, and M95 were found to be 
homologous with those of B cells derived from inflamed salivary 
glands and, except for sample M95, all were also homologous 
with stereotypic RFs, i.e., VH- CDR3s in samples M93- I and M94 
showed homology with stereotypic V3- 7- RFs, and VH- CDR3 
in sample M88 showed homology with stereotypic V1- 69- RFs 
(Figure 1; see also Supplementary Tables 2 and 3, available on 
the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41263/ abstract). Of note, sample M91 did 
not display a VH-CDR3 sequence that was homologous with ste-
reotypic V1- 69- RFs, although this salivary gland tissue sample 
expressed the canonical V1- 69- RF gene combination of IGHV1-
69/IGHJ4 and IGKV3-20. Salivary gland sample M86 shared 
VH- CDR3 homology with an IGHV3-30–encoded HCV- associated 
MALT lymphoma (Figure 1).
Expression­of­monospecific­RFs­in­most­SS-­associated­
MALT lymphoma salivary gland samples. We produced, in 
total, 12 recombinant IgM antibodies from the MALT lymphoma 
salivary gland samples in our study, i.e., samples M86, M89, M91, 
M93- I, M94, and M96, and from 6 MALT lymphoma salivary gland 
samples from our earlier study, i.e., samples M5, M8, M11, M14, 
M21, and M22 (9). Of the salivary gland tissue from patient M93, 
we produced 2 recombinant IgM antibodies, M93- IA and M93- IB, 
which differed by 4 aa in IGHV. Of sample M96, we produced 2 
recombinant IgM antibodies, M96- A and M96- B, which differed by 
2 aa in the VH- CDR3 (see Supplementary Figure 1 [http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41263/ abstract]).
The IgM antibodies produced from the MALT lymphoma sam-
ples were tested by ELISA for binding to insulin, actin, LPS, human 
IgG, SSA/Ro52, and SSA/Ro60. Except for samples M89, M8, 
and M14 in our earlier study, the IgM antibodies from all other MALT 
lymphoma salivary gland samples reacted with IgG and did not 
bind to any of the other antigens. The IgM antibodies from samples 
M91 and M96- B showed the strongest IgG- Fc binding (Figures 2A 
and B). It was noted that the M96-A IgM antibody showed a much 
weaker binding to IgG-Fc than the M96-B IgM antibody.
Figure  1. VH–third complementarity- determining region (CDR3) amino acid sequence homology of salivary gland mucosa-associated 
lymphoid tissue (MALT)–type lymphomas of patients M86, M88, M93-IB, M94, and M95 with 4 stereotypic rheumatoid factors (RFs) and with a 
MALT lymphoma (MALT-L) from a hepatitis C virus (HCV)–infected patient. VH-CDR3 homology is calculated as a percentage of identical (red) 
and similar (blue) amino acids.
BENDE ET AL 1334       |
Overall, among our panel of 12 salivary gland MALT lym-
phoma IgM antibodies, 9 (75%) showed strong monoreactive RF 
activity. This panel included 5 stereotypic RFs, i.e., 1 V1- 69- RF 
(sample M11), 3 V3- 7- RFs (samples M5, M93- I, and M94), and 
the newly recognized IGHV3-30–encoded RF (sample M86).
Recurrent replacement mutations in the IGHV and 
IGKV genes of RFs. We aligned the aa sequences of the IGHV1-
69– and IGHV3-7–encoded salivary gland MALT lymphoma 
RFs, including 3 IGHV1-69–encoded RFs (samples M9, M11, 
and M22) and 2 IGHV3-7–encoded RFs (samples M5 and 
Figure 2. MALT lymphoma IgM antibodies characterized as high- affinity monoreactive RFs. In enzyme- linked immunosorbent assays (ELISAs), 
IgM derived from MALT lymphoma salivary gland samples M86, M91, M93- I, M94, and M96 show specific binding to coated human IgG (A), with 
different binding affinities (B). Values on the y-axis are the absorbance measured at 450 nm. Sample M8 is an IgM from a patient with Sjӧgren’s 
syndrome– associated MALT lymphoma who was analyzed previously and does not show RF activity. Sample CLL57 is an IGV-gene–unmutated 
IgM derived from a patient with B cell chronic lymphocytic leukemia (CLL) and shows strong polyreactivity. Black boxes indicate positive ELISA 
results at all IgM concentrations tested; the gray- shaded box indicates positive ELISA results at the 2 highest IgM concentrations tested. The 
IgMs were tested in at least 4 concentrations, i.e., 125, 250, 500, and 1,000 ng/ml. LPS = lipopolysaccharide (see Figure 1 for other definitions).
Figure 3. Alignment of amino acid sequences of IGHV1-69–, IGHV3-7–, and IGKV3-15– encoded RFs of salivary gland MALT lymphomas. 
Boxes highlight shared somatic replacement mutations, i.e., S36T in the VH- CDR1 of samples M91 and M9, I59L in the VH- CDR2 of samples 
M91 and M11, and A65P in the VH- CDR2 of samples M88, M9, M11, and M22 (A), Q58P in the VH- CDR2 of samples M93IB and M6 (B), and 
Q106H in the VK- CDR3 of samples M89, M93, M94, M96, M6, and M5 (C). Somatic replacement mutations in the VH- CDR3 are underlined. 
FR1 = framework region 1 (see Figure 1 for other definitions).
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M6) from our earlier study (9). Our results demonstrated that 
the IGHV1-69–encoded RFs shared an A65P mutation (sam-
ples M88, M9, M11, and M22) or an I59L mutation (sam-
ples M91 and M11) in the VH- CDR2, while an S36T mutation 
in the VH- CDR1 was seen in 2 samples (M91 and M9). In 
the IGHV3-7–encoded RFs, we found a Q58P mutation that 
was shared between salivary gland samples M93- I and M6 
only. Of note, samples M6 and M9 were from a patient with 
gastric MALT lymphoma and a patient with tonsillar MALT 
lymphoma (9).
Alignment of 8 IGKV3-15 aa sequences, including IGKV3-15 
sequences of 2 stereotypic V3- 7- RF–expressing MALT lymphoma 
salivary gland tissue samples from our previous study, demon-
strated that all stereotypic V3- 7- RFs (in samples M93, M94, M5, 
and M6) possessed a Q106H mutation in their VK- CDR3 region. 
In addition, an IGHV4-59–expressing MALT lymphoma (sam-
ple M89), which did not show RF activity, and an IGHV3-30.3–
expressing RF (sample M96) also shared this Q106H mutation 
(Figures 3A–C).
Contribution­of­somatic­mutations­to­the­affinities­
of the MALT lymphoma RFs. We produced recombinant var-
iants of the IgM antibodies of MALT lymphoma salivary gland 
samples M91, M93- I, M94, and M96, in which somatic mutations 
in IGHV and/or IGKV were reverted to their respective germline 
configuration. Subsequently, we measured their affinity for IgG 
using surface plasmon resonance.
Reversion of the 4 replacement mutations in IGHV in MALT 
lymphoma salivary gland sample M91 had little effect on RF affinity 
(Figures 4A and B; compare the findings between bar A and bar 
B). However, when 2 replacement mutations in the VH- CDR3 (Fig-
ure 3) were also reverted, the RF affinity was completely lost (Fig-
ures 4A and B; compare the findings of bars A and B with bar C).
The 2 native stereotypic V3- 7- RF variants of sample M93-I 
(variants M93-IA and M93-IB), which had 4 dissimilar aa in their 
IGHV sequences, had the same affinity for IgG- Fc (Figures  4A 
and B; compare the findings in bar D with bar E). All IgM variants 
in sample M93- I in which IGHV, with or without the VH- CDR3 
and with or without IGKV, were reverted to germline configura-
tion showed slightly higher affinities for IgG- Fc when compared to 
the natural IgM antibodies in sample M93-I (M93-IA and M93-IB) 
(Figures 4A and B; compare the findings in bars F, G, H, I, J, K, 
and L with bars D and E). Even a completely reverted IgM of M93-
I, in which the H106Q mutation in VK-CDR3 was also reverted, 
showed an affinity that was similar to that of the naturally mutated 
M93-IA and M93-IB antibodies (Figures 4A and B; compare bar 
M with bars D and E). The 106- H mutation in the VK- CDR3, how-
ever, proved to be as important for RF affinity, as was illustrated 
by the 3 variant pairs (H and I, J and K, and L and M in Figures 4A 
and B), which showed higher RF affinities in the mutated 106- H 
Figure 4. Binding affinities of MALT lymphoma RFs and germline- reverted variants for human IgG, as measured by surface plasmon resonance 
assay. A, IGHV and IGKV configurations for the native lymphoma RFs and germline- reverted variants of lymphoma RFs, are shown, along with 
their binding constants (KD) to indicate affinity for human IgG. B, Histograms display the 1/KD values of the native and germline- reverted variants 
of lymphoma RFs. Each letter to the left of the bars for each sample represents an individual recombinantly produced IgM antibody. NB = no 
binding; 106- H = histidine mutation on position 106 of VK- CDR3; 106- Q = germline glutamine on position 106 of VK- CDR3 (see Figure 1 for 
other definitions).
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than in the 106- Q germline configuration. Most exemplary in this 
respect is the complete loss of RF affinity of M93- IA and M93- IB 
when the naturally mutated IgM antibodies were expressed with 
IGKV, in which only 106- Q was in germline configuration (Fig-
ures 4A and B; compare bars N and O).
The V3- 7- RF–expressing IgM antibodies in salivary gland 
sample M94, in which the 6 replacement mutations in IGHV were 
reverted, displayed a slightly higher RF activity as compared to its 
native mutated variant. However, when the 2 replacement muta-
tions in IGKV were also reverted, the RF activity was completely 
lost, which was already the case when the 106- H mutation was 
preserved (Figures 4A and B; compare bar R and bar S).
Finally, of the natural variants in salivary gland sample M96, 
the M96-B variant, which expressed dissimilar aa at 2 positions 
in the VH-CDR3 as compared to variant M96-A, showed a much 
higher affinity for IgG-Fc. Reversion of the 12 replacement muta-
tions in IGHV in the M96- B variant resulted in the complete loss 
of RF activity  (Figures 4A and B; compare bars T and U with bar 
V). Of note, the affinity measurements in MALT lymphoma sali-
vary gland variants M96- A and M96- B correlated nicely with the 
results of the RF ELISA (as shown in Figure 2).
DISCUSSION
The results of this study demonstrate that in most, but 
not all, MALT lymphomas occurring in patients with SS, BCRs 
with strong RF reactivity are expressed. Taken together with the 
results of a previous study by Martin et al (18) on 2 SS- associated 
MALT lymphomas, a total of 14 IgM antibodies of patients with 
SS- associated salivary gland MALT lymphoma have been pro-
duced recombinantly, of which 11 showed RF specificity. Five of 
these were stereotypic RFs, i.e., 1 sample with V1- 69- RF, 3 sam-
ples with V3- 7- RFs, and 1 sample (M86) that shared VH- CDR3 
homology with an IGHV3-30–encoded HCV- associated MALT 
lymphoma, which could be considered as a newly identified ste-
reotypic RF- BCR group. 
Remarkably, all MALT lymphoma IgM antibodies that showed 
RF activity expressed an Igκ light chain that was encoded either 
by IGKV3-15 (samples M5, M86, M93- I, M94, and M96) or by 
IGKV3-20 (samples M11, M21, M22, and M91). Of the 3 MALT 
lymphoma IgM antibodies without RF activity (samples M8, M14, 
and M89), only those in the salivary gland tissue of patient M89 
expressed an IGKV3-15–encoded Igκ. In 5 MALT lymphoma 
samples, we did not produce IgM antibodies but we garnered 
information about their IGHV sequences with or without IGKV 
(samples M83, M87, M88, M93- II, and M95); sample M95 also 
co- expressed IGKV3-15 and an IGHV3-48–encoded Ig heavy 
chain with VH- CDR3 homology with stereotypic V3- 7- RFs. 
Sample M83 expressed an IGHV3-74–encoded Ig heavy chain. 
IGHV3-74 was also recently identified, by mass spectrometric 
sequencing of serum RFs, as one of the IGHV aa sequences 
present in 9 of 15 patients with SS (23). Finally, sample M88 
expressed a stereotypic V1- 69- RF Ig heavy chain. These data 
indicate that the MALT lymphoma salivary gland IgM antibodies in 
samples M83, M88, and M95 are likely also RFs.
Stereotypic RF reactivity is not unique to salivary gland MALT 
lymphomas. We have also demonstrated stereotypic RF reactivity 
in 2 samples from patients with gastric MALT lymphoma (9), 2 
with CLL (12,15), and 4 with HCV- related B cell lymphoma (10). 
It is remarkable that whereas most SS-associated salivary gland 
MALT lymphomas express RFs, the frequency of stereotypic RF 
B cells in inflamed salivary glands of SS patients was found to be 
low (24,25). This suggests that RF B cells in SS, once recruited 
in an inflamed salivary gland and activated by IgG immune com-
plexes, e.g., IgG- SSA/SSB, have a growth advantage and are 
prone to transform (25).
Analysis of IGHV1-69–encoded RFs demonstrated a lim-
ited number of recurrent replacement mutations, i.e., A65P and 
I59L in the VH- CDR2, and S36T in the VH- CDR1, which were 
present in 4 RFs, 2 RFs, and 2 RFs, respectively (of a total of 5). 
Among the 14 reported SS- associated MALT lymphoma–derived 
IGHV1-69 sequences, whose RF activity was not explored in vitro, 
the A65P mutation was not found, whereas I59L was found in 2 
cases and S36T was found in 3 cases (26,27). In the 11 IGHV1- 
69–encoded RFs found in HCV- infected patients with cryoglobu-
linemia, A65P was present in 3 cases, and both I59L and S36T 
were found in 2 cases (28). 
In 2 of 4 stereotypic V3- 7- RFs, we identified a recurrent 
Q58P mutation in the VH- CDR2. In the literature, Q58P was 
reported to be present in 2 of 4 IGHV3-7 sequences in the salivary 
glands of patients with SS- associated MALT lymphoma (26,27). 
Alignment of the corresponding IGKV3-15 aa sequences of our 
stereotypic V3- 7- RFs showed that all 4 carried a Q106H replace-
ment mutation in their VK- CDR3 region. Interestingly, the IGHV4-
59–expressing salivary gland MALT lymphoma from patient M89, 
which did not display RF activity, and the IGHV3-30.3–expressing 
RF from patient M96 both harbored a Q106H mutation in the VK- 
CDR3 as well. In the literature, it was reported that Q106H was 
found in an SS- associated MALT lymphoma (18) and in a stere-
otypic V3- 7- RF from a patient with CLL (12). For both of these 
lymphomas, in vitro RF activity was demonstrated (12,18).
We observed that MALT lymphoma salivary gland sample 
M91 expressed the stereotypic combination of IGHV1-69 and 
IGKV3-20. However, this RF does not share VH- CDR3 homology 
with stereotypic V1- 69- RFs. Reversion of its 4 IGHV replace-
ment mutations showed a small reduction in RF affinity, and when 
the 2 replacement mutations in the VH- CDR3 were also reverted, 
IgG binding was completely lost.
These results were recently clarified in a description of the 
crystal structure of an IGHV1-69/IGKV3-20–encoded RF (YES8c) 
in complex with IgG1- Fc (29). The YES8c RF also does not dis-
play VH- CDR3 homology with V1- 69- RFs. The VH- CDR3 in 
sample M91 shared 47% aa sequence homology with the VH- 
CDR3 of YES8c. In total, atoms of 12 IGHV aa of YES8c were 
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shown to interact with the CH2 and CH3 regions of IgG1- Fc (Fig-
ure 5A). Alignment of the sequences in samples M91 and YES8c 
demonstrates that 7 of these 12 aa are shared between M91 and 
YES8c. In sample M91, only 2 of the 4 replacement mutations 
in the IGHV region (S36T and I59L) were contact residues with 
IgG- Fc, of which the I59L mutation, present both in M91 and in 
YES8c, led to a lower affinity in YES8c. Since serine and thre-
onine are similar, the S36T mutation likely does not add much 
to the affinity in sample M91 (29). It thus is envisioned that the 
reversion of these 4 replacement mutations in sample M91 will 
yield a small difference in RF affinity (Figure 4). Interestingly, the 
R111.1- G mutation in the M91 VH- CDR3 resulted in an identical 
aa sequence as that in YES8c. The 111.1- G mutation was shown 
to interact with IgG1- Fc (Figure 5B). The contribution of a patch 
of 4 or 5 contiguous aa in the VH- CDR3 to the Fc- IgG1 binding 
affinity was substantiated by the complete loss of RF activity upon 
germline reversion of 2 mutations within this patch. Eight IGKV 
aa of YES8c, of which 7 aa are identical to those in M91, were 
shown to interact with IgG1- Fc (Figure 5A). Finally, the VH- CDR3 
of YES8c shared 73% homology with the VH- CDR3 expressed by 
an SS- associated salivary gland MALT lymphoma from GenBank 
(sample T580B) (Figure 5B).
The results of the IgG binding studies of the 12 constructed 
variants of the RFs in MALT lymphoma salivary gland sample 
M93- I were, in part, more difficult to interpret. In sample M93- I, a 
completely germline- reverted IGHV/IGKV variant showed a simi-
lar RF affinity as that of the native IgM antibodies of M93- IA and 
IB. All reverted variants of IGHV, with or without the VH- CDR3 
and with or without IGKV, displayed even slightly enhanced RF 
affinities. However, the 106- H mutation of the VK- CDR3 contrib-
uted to the RF affinity, which was illustrated by the variant pairs 
that differed only with respect to each other between 106- H and 
106- Q. Most explanatory in this respect is the complete loss of 
RF affinity when the naturally mutated IgM antibodies of M93- IA 
and IB were expressed with IGKV, in which only 106- Q was in 
germline configuration (Figures 4A and B, bar N and bar O). Unfor-
tunately, of the stereotypic V3- 7- RFs, no crystal structure has as 
yet been reproduced. Our observation that reversion of particular 
replacement mutations in RFs can lead to higher IgG- Fc affinities 
has been described before (28,29).
A completely germline- reverted IGHV/IGKV variant of V3- 
7- RF in sample M94 did not show any IgG binding. The VH- CDR3 
of M96- A harbored 2 extra replacement mutations as compared 
to that of M96- B, and yet it showed a much lower affinity for IgG, 
indicating that the germline aa at this position are important for 
RF affinity. Moreover, reversion of 12 IGHV replacement mutations 
both in M96- A and in M96- B resulted in a complete loss of IgG 
binding.
Taken together, these findings indicate that somatic IGV-
gene mutations contribute differently to the affinity of the RFs for 
IgG- Fc. Germline reversion of replacement mutations in IGHV, 
including the VH- CDR3 and, if applicable, also IGKV, resulted in 
lower RF affinities of the IgM antibodies of samples M91, M94, 
and M96. The affinities of the RFs varied, with binding  constants 
(KD) ranging between 91 nM and 12 nM. These affinity values 
are lower than we have previously measured for tetanus toxoid– 
specific antibodies, which were found to have KD values between 
1.9 nM and 0.1 nM (22). Overall, the experiments showing 
Figure 5. Alignment of the IGHV1-69–encoded RFs of YES8c and M91. A, Somatic replacement mutations, as compared with the IGHV1-69 
and IGKV3-20 germline sequences, are indicated. B, Alignment of the VH- CDR3 amino acid sequences in YES8c, M91, and the homologous 
T580B, which originated from a patient with a Sjögren’s syndrome–related MALT lymphoma, are indicated. Somatic replacement mutations are 
underlined. Gray- shaded boxes highlight the amino acids of RFs in YES8c that are the contact residues with IgG- Fc. FR1 = framework region 
1 (see Figure 1 for other definitions).
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reversion of IGV-gene mutations have demonstrated that the RFs 
are affinity- selected. Even the germline- converted RFs of M93- IA 
and IB, which displayed an affinity similar to its naturally mutated 
variant, indicated that although the IGV-gene mutations did not 
enhance the RF affinity, they still seemed to be selected to pre-
serve the RF affinity and specificity.
Recently, it was shown that the RF epitopes of monomeric 
IgG in solution are shielded for soluble RFs and RF- expressing 
B cells. The RF epitopes may become accessible, e.g., after 
physical adsorption on a hydrophobic surface in ELISA plates, by 
heat treatment or in vivo by binding of IgG to its antigen- forming 
IgG immune complexes (30). The fact that RF B cells can be 
activated only by IgG in immune complexes was shown before 
(31,32). Moreover, in a mouse model, RF B cells were shown to 
be activated by IgG–chromatin complexes through the synergistic 
engagement of the RF- BCR and Toll- like receptor 9 (TLR- 9) (33). 
As it is known that SSA/SSB are part of a ribonucleoprotein com-
plex containing single- stranded RNA stem- loop structures, RF B 
cells in SS salivary glands may also be activated by IgG–SSA/
SSB immune complexes via the RF- BCR and TLR- 7. In support 
of this, it has recently been shown that IgG and IgA anti- SSA/
Ro52, Ro60, and SSB/La48 are produced by ~30% of salivary 
gland plasmablasts in patients with SS, and the correspond-
ing autoantibodies are found in the serum (34). Similarly, using 
biotin- labeled SSA/Ro60 in immunohistochemical analyses, we 
detected in situ anti- SSA/Ro60–specific autoantibodies, as well as 
plasma cells, producing anti- SSA/Ro60–specific autoantibodies 
in salivary gland samples from 3 patients with SS and in all 5 
tested samples from patients with SS- associated MALT lym-
phoma (samples M14 and M93–M96) (see Supplementary Figure 
2, available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.41263/ abstract).
Somatic mutations in IGV genes are classically introduced 
during T helper cell–dependent germinal center (GC) reactions. 
However, it is unlikely that T helper cells specific for IgG pep-
tides would escape negative selection during their development. 
The most obvious pathway for RF B cells to receive T cell help is 
that autoantigens that are contained in IgG–immune complexes 
are internalized and delivered to major histocompatibility com-
plex class II–processing compartments, leading to the presenta-
tion of peptides of autoantigens, e.g., of SSA/Ro52/Ro60 and 
SSB/La48 (35,36). The fact that highly somatically mutated IgG 
autoantibodies against SSA/Ro52, Ro60, and SSB/La48 pro-
teins are frequently found in patients with SS and in patients with 
systemic lupus erythematosus indicates that these proteins can 
initiate a GC reaction, in which the autoreactive B cells receive 
cognate help from autoreactive T cells that recognize peptides of 
SSA/Ro52, Ro60, and SS/La48 (34,37,38). These same T helper 
cells may thus also permit indirectly, and perhaps less efficiently, 
a GC reaction of RF B cells. Normally, a proportion of B cells that 
have acquired high- affinity BCRs undergo class switch recombi-
nation and become expressed as IgG. However, class- switched 
RF B cells that express IgG will bind neighboring IgG molecules, 
which likely will result in overstimulation and autodeletion of these 
IgG- expressing RF B cells. Similarly, IgM- RF–expressing B cells in 
which the affinities are too high might become overstimulated by 
IgG bound to its antigen, and thereby become anergic or deleted. 
The possibility that chronic stimulation of RF B cells can lead to 
anergy has indeed been demonstrated in some patients with SS 
and patients with chronic HCV infection, whose peripheral blood 
harbored a population of expanded, unresponsive CD21−/low RF B 
cells (39–41).
In conclusion, the majority of SS-associated salivary gland 
MALT lymphomas express BCRs with monoreactive, high- affinity 
RF activity. These RFs carry somatic mutations in their IGV genes 
and are affinity- selected for IgG binding. In patients with SS, we 
hypothesize that IgG–autoantigen complexes in inflamed salivary 
glands provide a growth advantage to RF- expressing B cells and 
are key in the pathogenesis of RF- expressing MALT lymphoma.
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